OncoCyte Corporation Stock price

Equities

OCX

US68235C2061

Biotechnology & Medical Research

Delayed Nasdaq 02:53:06 2024-03-28 pm EDT 5-day change 1st Jan Change
2.94 USD -1.34% Intraday chart for OncoCyte Corporation -3.61% +17.60%
Sales 2023 * 1.51M Sales 2024 * 2.48M Capitalization 24.62M
Net income 2023 * -20M Net income 2024 * -24M EV / Sales 2023 * 16.3 x
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * 9.94 x
P/E ratio 2023 *
-1.19 x
P/E ratio 2024 *
-1.04 x
Employees 76
Yield 2023 *
-
Yield 2024 *
-
Free-Float 94.23%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.34%
1 week-3.61%
Current month+1.03%
1 month-0.68%
3 months+17.60%
6 months-8.12%
Current year+17.60%
More quotes
1 week
2.93
Extreme 2.93
3.06
1 month
2.90
Extreme 2.9
3.07
Current year
2.57
Extreme 2.57
3.82
1 year
2.08
Extreme 2.08
7.40
3 years
2.08
Extreme 2.08
125.00
5 years
2.08
Extreme 2.08
131.40
10 years
2.08
Extreme 2.08
204.80
More quotes
Managers TitleAgeSince
Chief Executive Officer 42 20-07-31
Director of Finance/CFO 29 21-06-30
Chief Tech/Sci/R&D Officer - 21-08-31
Members of the board TitleAgeSince
Director/Board Member 64 15-12-22
Director/Board Member 81 09-08-31
Director/Board Member 65 22-11-29
More insiders
Date Price Change Volume
24-03-28 2.94 -1.34% 17 061
24-03-27 2.98 -0.60% 1,766
24-03-26 2.998 -0.68% 11,395
24-03-25 3.018 -1.36% 1,780
24-03-22 3.06 +0.33% 2,519

Delayed Quote Nasdaq, March 28, 2024 at 02:53 pm EDT

More quotes
Oncocyte Corporation is a precision diagnostics company. The Company is engaged in the development of Oncocytes tests and the acquisition of proprietary molecular technologies in the fields of oncology and transplantation. The Company's products include DetermaIO, VitaGraft, and DetermaCNI. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaIO measures the expression level of 27 selected genes, which are interpreted through the use of a proprietary algorithm (patent pending) which computes a quantitative score (IO Score) that incorporates information from the immune inflammatory infiltrates within and around the tumor, combined with information from the wound response surrounding the tumor. Its pipeline test, DetermaCNI, is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. VitaGraft is a blood-based solid organ transplantation monitoring test.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
2.98 USD
Average target price
3.533 USD
Spread / Average Target
+18.57%
Consensus
  1. Stock
  2. Equities
  3. Stock OncoCyte Corporation - Nasdaq